Michael Ohanessian

Michael Ohanessian serves as Interim CEO at Haemokinesis. Haemokinesis operates in the medical devices sector with approximately 31.0 employees. The company is headquartered in Melbourne, Victoria.

Industry & Role Insights

• • MessageCEO tracks 1,888 executives in the medical devices sector.
• • 2,608 executive contacts are available in Victoria.
• • Our database includes 201,469 c suite-level executives.

Cloudflare DNS Outlook Microsoft Office 365 CloudFlare Hosting Mobile Friendly Google Maps Google Font API Google Maps (Non Paid Users) Google Analytics Gravity Forms Google Tag Manager WordPress.org Remote

blood banking immunohaematology trauma poc hospitals clinical diagnostics blood diagnostics emergency medicine blood banking systems automated analyzers serology tests antibody screening crossmatching blood typing hospital solutions laboratory solutions point-of-care testing blood group testing technological innovation iso 9001 iso 13485 sensitive testing specificity fast results semi-automated systems fully automated systems daymate s stargel10 status1 healthcare technology trauma care clinical laboratory efficiency blood group serology diagnostic reagents customer support technical support global distribution laboratory automation regulatory compliance market access high throughput analyzers test sensitivity patient outcomes healthcare accessibility medicinal diagnostics in vitro diagnostics life-saving technology medical professionals patient care distributor networks research & development lab testing efficiency hospital & health care

YM

Yahia Megahed CEO at 360Imaging

HA

Hugo Azevedo Chief Technology Officer at 3B Scientific

MP

Marie-Laure Pochon CEO & President at 3DISC

KD

Khanh Duy Co-CEO at 3D-Side

K

Khanh Co-CEO at 3D-Side

Outreach Guidance — medical devices Sector

Executives like Michael Ohanessian in the medical devices sector receive targeted outreach from sales teams, recruiters, and investors. To stand out, personalize your message with industry-specific context and a clear, specific value proposition relevant to their role at Haemokinesis.

Michael Ohanessian's Position in the MessageCEO Database

• •Michael Ohanessian is 1 of 1 verified executive contact we track at Haemokinesis.
• •1,787 verified executive contacts in medical devices are in the MessageCEO database.
• •2,562 verified executive contacts in Victoria are in the database.
• •31 verified contacts work at medical devices companies in the 31.0 employee range (same size as Haemokinesis).

Executive contact data compiled from public business filings, LinkedIn public profiles, company press materials, and verified outbound email testing. We do not publish personal addresses or sensitive identifiers. Methodology & sources · Removal requests handled at /remove-info · Updated July 2026.

How do I reach Michael Ohanessian directly?

Michael Ohanessian's verified email address is available to MessageCEO Pro subscribers. They currently serve as Interim CEO at Haemokinesis. Access direct contact info to skip gatekeepers and reach the decision maker.

What company does Michael Ohanessian work for?

Michael Ohanessian is Interim CEO at Haemokinesis, a company in the medical devices sector with 31.0 employees. The company is based in Melbourne, Victoria.

Can I pitch or sell to Michael Ohanessian?

As Interim CEO at Haemokinesis, Michael Ohanessian is a key decision-maker in the medical devices sector. MessageCEO Pro gives you verified email to reach Michael Ohanessian directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is Michael Ohanessian in?

Michael Ohanessian works in the medical devices industry as Interim CEO at Haemokinesis. MessageCEO provides verified contact information for executives across all major industries.

Is Michael Ohanessian's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. Michael Ohanessian's profile is kept up-to-date with the latest available information.

Last updated: July 19, 2026